From the excellent Health Lawyers Weekly (AHLA member benefit), here's the table of contents from the September 29 issue:Top StoriesIOM Issues Recommendations For Improving FDA Post-Market Drug Surveillance -- The Food and Drug Administration’s (FDA's) ability to oversee the safety of prescription drugs after they hit the market is undermined by a number of systemic deficiencies--including